









Markets
/
Stocks
/
nasdaq-xfor
/

X4 Pharmaceuticals Inc

XFOR

3.560USD

-0.100-2.73%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

89.52MMarket Cap

LossP/E TTM



X4 Pharmaceuticals Inc

3.560

-0.100-2.73%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of X4 Pharmaceuticals Inc

Currency: USD Updated: 2026-02-06

Key Insights

X4 Pharmaceuticals Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 114 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.00.In the medium term, the stock price is expected to remain stable.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

X4 Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

114 / 159

Overall Ranking

357 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

X4 Pharmaceuticals Inc Highlights

StrengthsRisks

X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. It has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.

Growing

The company is in a growing phase, with the latest annual income totaling USD 2.56M.

Overvalued

The company’s latest PE is -0.40, at a high 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 19.18K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 13.21.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

8.000

Target Price

+118.58%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of X4 Pharmaceuticals Inc is 5.78, ranking 151 out of 159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 1.76M, representing a year-over-year increase of 215.18%, while its net profit experienced a year-over-year increase of 18.75%.

Score

Industry at a Glance

Previous score

5.78

Change



Financials

6.37

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.58

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.05

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

X4 Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of X4 Pharmaceuticals Inc is 7.05, ranking 101 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -0.40, which is -48540.51% below the recent high of 195.65 and -78186.53% above the recent low of -316.20.

Score

Industry at a Glance

Previous score

7.05

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 114/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of X4 Pharmaceuticals Inc is 8.50, ranking 31 out of 159 in the Pharmaceuticals industry. The average price target is 7.50, with a high of 13.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

8.000

Target Price

+118.58%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

173

Total

Median

Average

Company name

Ratings

Analysts

X4 Pharmaceuticals Inc

XFOR

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of X4 Pharmaceuticals Inc is 2.84, ranking 153 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 4.03 and the support level at 3.31, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

2.84

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.015

Sell

RSI(14)

41.662

Neutral

STOCH(KDJ)(9,3,3)

26.975

Sell

ATR(14)

0.187

Low Volatility

CCI(14)

-82.443

Neutral

Williams %R

92.437

Oversold

TRIX(12,20)

-0.159

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

3.810

Sell

MA10

3.739

Sell

MA20

3.756

Sell

MA50

3.806

Sell

MA100

3.640

Sell

MA200

3.259

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of X4 Pharmaceuticals Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 9.67%, representing a quarter-over-quarter decrease of 71.83%. The largest institutional shareholder is The Vanguard, holding a total of 3.42M shares, representing 3.92% of shares outstanding, with 15.71% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Perceptive Advisors LLC

5.91M

The Vanguard Group, Inc.

Star Investors

410.49K

+77.02%

New Enterprise Associates (NEA)

3.23M

+44.77%

Bain Capital Life Sciences Investors, LLC

2.44M

+391.26%

Empery Asset Management, L.P.

2.39M

BVF Partners L.P.

2.23M

Nantahala Capital Management, LLC

2.23M

Trails Edge Capital Partners LP

1.57M

Rosalind Advisors, Inc.

1.54M

Deep Track Capital LP

1.12M

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of X4 Pharmaceuticals Inc is 2.79, ranking 119 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.43. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. X4 Pharmaceuticals Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.